Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:05:56.709Z.
Consensus retrieved: 2026-10-06T09:34:48.502Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:05:56.709Z.
Quote observation: 2026-10-06T15:05:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a536da8eae666eb645f8b33c150b74020e4e9b3ff535c5becd935f4d76daa57
Forward PE Ratio (N/A) = Dated Quote Price ($1.47) / Consensus Forward EPS ($-2.14)
FORWARD PE RATIO
N/A
Bionano Genomics, Inc.
Market Cap
$16.81M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bionano Genomics, Inc. (BNGO) | $16.81M | N/A |
| Lipocine Inc. (LPCN)vs › | $16.98M | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.58M | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.08M | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.58M | N/A |
| Cosmos Health Inc. (COSM)vs › | $18.45M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.15M | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.70M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.47, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.14 | $-2.15 – $-2.13 | 1 | n/m |
| 2027-12-31 | $-0.97 | $-0.97 – $-0.97 | 1 | n/m |
| 2028-12-31 | $-0.52 | $-0.52 – $-0.52 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
